Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Bert L. Lum"'
Autor:
Patricia M. LoRusso, Jennifer A. Low, Josina C. Reddy, Charles M. Rudin, Daniel D. Von Hoff, Karin Jorga, Jin Yan Jin, Sravanthi Cheeti, Bert L. Lum, Richard A. Graham
Related CCR Translation from Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445d125ac34f7cf31441c6e5b21da204
https://doi.org/10.1158/1078-0432.22442520.v1
https://doi.org/10.1158/1078-0432.22442520.v1
Autor:
Patricia M. LoRusso, Jennifer A. Low, Josina C. Reddy, Charles M. Rudin, Daniel D. Von Hoff, Karin Jorga, Jin Yan Jin, Sravanthi Cheeti, Bert L. Lum, Richard A. Graham
Purpose: In a phase I trial for patients with refractory solid tumors, hedgehog pathway inhibitor vismodegib (GDC-0449) showed little decline in plasma concentrations over 7 days after a single oral dose and nonlinearity with respect to dose and time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::180a91f52a60c76662c36a5c9d52002f
https://doi.org/10.1158/1078-0432.c.6519234
https://doi.org/10.1158/1078-0432.c.6519234
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 410-418 (2020)
Clinical and Translational Science
Clinical and Translational Science
Pharmacokinetic (PK) variability in cancer clinical trials may be due to heterogeneous populations and identifying sources of variability is important. Use of healthy subjects in clinical pharmacology studies together with detailed knowledge of the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102f87ac259c3790b339fe1fe0957779
https://doaj.org/article/d39a829c04af4361812a1c06dda91a62
https://doaj.org/article/d39a829c04af4361812a1c06dda91a62
Autor:
D. Russell Wada, Hanbin Li, Angelica Quartino, Bert L. Lum, Whitney P. Kirschbrown, Jin Y. Jin, Amit Garg, Ranvir Mangat
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The aim of the study was to characterize the population pharmacokinetics (PK) of the intravenous formulation of trastuzumab, assess the impact of patient and pathological covariates on trastuzumab PK, and perform simulations to support dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35d11ca72d3b571c792eb414e89d29dc
http://europepmc.org/articles/PMC6394489
http://europepmc.org/articles/PMC6394489
Autor:
Harald A. Weber, Christian Jackisch, Bert L. Lum, Bohuslav Melichar, Gustavo Ismael, R. Elliott, Xavier Pivot, Vladimir Semiglazov, S.-B. Kim, Daniil Stroyakovskiy, C. Hillenbach
Publikováno v:
Annals of Oncology. 26:320-325
HannaH revealed consistent overall safety profiles between fixed-dose subcutaneous (s.c.) and weight-based intravenous (i.v.) trastuzumab (median follow-up 20 months). Event-free survival rates were balanced between i.v. and s.c. There was no associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a531d9bd01cfa7f4e324a91c9adcf883
https://doi.org/10.1093/annonc/mdu524
https://doi.org/10.1093/annonc/mdu524
Autor:
Bert L. Lum, Mark Stroh
Publikováno v:
Clinical Pharmacology & Therapeutics. 100:215-217
Therapeutic drug monitoring (TDM) aims to maintain circulating drug concentrations at a desired level to optimize clinical outcome. The vast majority of marketed drugs do not require TDM, suggesting the clinical benefit of TDM has not been sufficient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3693c4ab9a04394205ada170d4f2ad4
https://doi.org/10.1002/cpt.365
https://doi.org/10.1002/cpt.365
Publikováno v:
Anti-Cancer Drugs
The US Food and Drug Administration (FDA) issued a guidance document in 2010 on pharmacokinetic (PK) studies in renal impairment (RI) on the basis of observations that substances such as uremic toxins might result in altered drug metabolism and excre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34cccbd9d47c1dd17e0d162ab284399e
https://pubmed.ncbi.nlm.nih.gov/28542036
https://pubmed.ncbi.nlm.nih.gov/28542036
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer
Autor:
Hilary Calvert, Chris Twelves, Malcolm Ranson, Ruth Plummer, Scott Fettner, Michael Pantze, Jie Ling, Marta Hamilton, Bert L. Lum, Ashok Rakhit
Publikováno v:
Anti-Cancer Drugs. 25:832-840
In vitro, erlotinib (0-30 µmol/l) and C-labelled midazolam (MDZ) (5 µmol/l) were incubated with human liver microsomes; separately, microsomes were preincubated with erlotinib (10 µmol/l) before the addition of MDZ. Results showed a time-dependent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208910b37631dd8f1e4265a8b1e7774c
https://doi.org/10.1097/cad.0000000000000099
https://doi.org/10.1097/cad.0000000000000099
Publikováno v:
Cancer Chemotherapy and Pharmacology. 73:737-747
The aim of this study was to characterize trastuzumab population pharmacokinetics (PKs) in patients with human epidermal growth factor receptor 2-positive advanced gastric or gastroesophageal junction cancer and the relationship of trastuzumab PK wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a49de1a379dfefb83a5cb497039d067
https://doi.org/10.1007/s00280-014-2400-5
https://doi.org/10.1007/s00280-014-2400-5
Autor:
Maik Hauschild, Bert L. Lum, Taral Patel, Graham Ross, Amit Garg, Jean-Francois Marier, Mike Brewster, Sandra M. Swain, Javier Cortes, Elza Grincuka, Jennifer Visich, V. McNally, My My Trinh, Norikazu Masuda, José Baselga, Ihsan Nijem, Iveta Kudaba
Publikováno v:
Anti-Cancer Drugs. 24:1084-1092
Pertuzumab is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined with trastuzumab plus docetaxel, pertuzumab improved progression-free and overall survival versus trastuzumab plus docetaxel in the phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbfb0f2b9a485347ac8e6112ab703063
https://doi.org/10.1097/cad.0000000000000016
https://doi.org/10.1097/cad.0000000000000016